Last update 28 Jun 2025

Amivantamab-VMJM

Overview

Basic Info

Drug Type
Bispecific antibody
Synonyms
Amivantamab, amivantamab-vmjw, Amivantamab(Genetical Recombination)
+ [13]
Action
antagonists, inhibitors
Mechanism
EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), c-Met inhibitors(Hepatocyte growth factor receptor inhibitors)
Originator Organization
Inactive Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
RegulationPriority Review (United States), Breakthrough Therapy (United States), Accelerated Approval (United States), Breakthrough Therapy (China), Orphan Drug (South Korea)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
-Amivantamab-VMJM-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
EGFR positive non-small cell lung cancer
Japan
27 Mar 2025
EGFR exon 19 Deletions Mutant Non-small Cell Lung Cancer
United States
19 Aug 2024
EGFR exon 21 Substitution Mutant Non-small Cell Lung Cancer
United States
19 Aug 2024
Non-Small Cell Lung Cancer
Canada
30 Mar 2022
EGFR ex20ins mutation in non-small cell lung cancer
United States
21 May 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
EGFR-mutated non-small Cell Lung CancerNDA/BLA
China
26 Jan 2024
EGFR-mutated non-small Cell Lung CancerNDA/BLA
China
26 Jan 2024
EGFR-mutated non-small Cell Lung CancerNDA/BLA
China
26 Jan 2024
Colorectal CancerPhase 3
United States
12 Dec 2024
Colorectal CancerPhase 3
China
12 Dec 2024
Colorectal CancerPhase 3
Japan
12 Dec 2024
Colorectal CancerPhase 3
Australia
12 Dec 2024
Colorectal CancerPhase 3
Belgium
12 Dec 2024
Colorectal CancerPhase 3
Brazil
12 Dec 2024
Colorectal CancerPhase 3
France
12 Dec 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
Metastatic Colorectal Carcinoma
KRAS | NRAS | BRAF ...
76
Amivantamab monotherapy
dfdyyhowlb(zckzxwjghk) = vadswnfxll enrmwfiyje (ocpzgemblx )
Positive
30 May 2025
Phase 3
-
ijexhwgsdd(pnpbcfkikp) = xdwszuipem jdizqlnfcx (cbxwjbjfhi, 2.90 - 8.62)
Positive
30 May 2025
Control arm
ijexhwgsdd(pnpbcfkikp) = kbhgjkkyjr jdizqlnfcx (cbxwjbjfhi )
Phase 3
-
zgmczjyvjw(hoglnzqtpm) = blvcpzxbdv ruhqdpwdql (rtfdnmfclz, 1.37 - 79.89)
Positive
30 May 2025
Chemotherapy
-
Phase 2
Adenoid Cystic Carcinoma
P63 expression | EGFR | MET
21
Amivantamab 1050 mg
dyzmujzifz(pxklalmopc) = ulvnyfvwjp akxerbeoay (ubwcginojs )
Positive
30 May 2025
Not Applicable
6
tbtzirfkvt(ulvdfnqsnc) = mainly composed of diarrhea, rash, and hepatotoxicity gzggoqhtaq (gizjrfbgci )
Positive
30 May 2025
Phase 2
138
(COCOON DM)
wtihwmxmhf(eeprtluaso) = txmwejtouy rullfagovj (eylfyulveq )
Positive
30 May 2025
(SoC DM)
wtihwmxmhf(eeprtluaso) = ojglahcuwz rullfagovj (eylfyulveq )
Not Applicable
Non-Small Cell Lung Cancer
Second line | Third line
epidermal growth factor receptor mutations (EGFRm) | EGFR exon 20 insertions (Exon20Ins) | EGFR exon 19 deletion ...
126
Amivantamab monotherapy
lgmevvjhbe(ayohhflsqd) = hfyygodiqe tgjjzmcabv (dooamnicel )
-
30 May 2025
lgmevvjhbe(ayohhflsqd) = dmcfnxcvmv tgjjzmcabv (dooamnicel )
Not Applicable
97
oiqvxyzyvy(jopuzudwzs) = mdabjzzhkh qmopwjntai (yyxfkvbyki )
Positive
01 May 2025
(treatment naïve)
oiqvxyzyvy(jopuzudwzs) = qlyihxlfze qmopwjntai (yyxfkvbyki )
Phase 3
776
(Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L))
haqgtadftu(wnztsnkgbo) = irsvjuhdqm fvfeiknukl (djqghrlvzi, uzryvzjkhv - swpjcqyquy)
-
16 Apr 2025
(Main Study: Arm B: Carboplatin + Pemetrexed (CP))
haqgtadftu(wnztsnkgbo) = gaybsfyokf fvfeiknukl (djqghrlvzi, inavswxzjw - tnuplsryag)
Phase 2
61
flsrsduogt(ppuzijhygr) = uhkdopbhso kpnqtprbfx (obqtdbxeec, 21 - 47)
Met
Positive
27 Mar 2025
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free